BRPI0520493A2 - usos de uma enzima, de um composto antifolato e de um agente de resgate de rota de folato, sistema terapêutico, e, métodos ex vivo para clivar um grupo l-glutamato terminal de um composto, para determinar a taxa e/ou extensão de clivagem de um composto e para clivar um composto - Google Patents
usos de uma enzima, de um composto antifolato e de um agente de resgate de rota de folato, sistema terapêutico, e, métodos ex vivo para clivar um grupo l-glutamato terminal de um composto, para determinar a taxa e/ou extensão de clivagem de um composto e para clivar um compostoInfo
- Publication number
- BRPI0520493A2 BRPI0520493A2 BRPI0520493-3A BRPI0520493A BRPI0520493A2 BR PI0520493 A2 BRPI0520493 A2 BR PI0520493A2 BR PI0520493 A BRPI0520493 A BR PI0520493A BR PI0520493 A2 BRPI0520493 A2 BR PI0520493A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- cleave
- enzyme
- antifolate
- therapeutic system
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 6
- 108090000790 Enzymes Proteins 0.000 title abstract 4
- 102000004190 Enzymes Human genes 0.000 title abstract 4
- 230000003432 anti-folate effect Effects 0.000 title abstract 3
- 229940127074 antifolate Drugs 0.000 title abstract 3
- 239000004052 folic acid antagonist Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 229940014144 folate Drugs 0.000 title abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title abstract 2
- 235000019152 folic acid Nutrition 0.000 title abstract 2
- 239000011724 folic acid Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L L-glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 title 1
- 238000003776 cleavage reaction Methods 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 230000007017 scission Effects 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 abstract 2
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USOS DE UMA ENZIMA, DE UM COMPOSTO ANTIFOLATO E DE UM AGENTE DE RESGATE DE ROTA DE FOLATO, SISTEMA TERAPêUTICO, E, METODOS EK VIVO PARA CLIVAR UM GRUPO L-GLUTAMATO TERMINAL DE UM COMPOSTO, PARA DETERMINAR A TAXA E/OU EXTENSãO DE CLIVAGEM DE UM COMPOSTO E PARA CLIVAR UM COMPOSTO. Um método para combater toxicidade causada por um composto antifolato de Fórmula I, em um indivíduo que tem sido administrado com o composto. O método compreende administrar ao indivíduo uma enzima que possui atividade de carbóxi-peptidase G. Um método de clivagem de um composto compreendendo um fragmento estrutural de Fórmula IV, o método compreendendo contatar o composto compreendendo o fragmento estrutural de Fórmula IV com uma enzima que possui atividade de carbóxi-peptidase G.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2005/003297 WO2007023243A2 (en) | 2005-08-24 | 2005-08-24 | Cleavage of antifolate compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0520493A2 true BRPI0520493A2 (pt) | 2009-05-12 |
Family
ID=36615646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0520493-3A BRPI0520493A2 (pt) | 2005-08-24 | 2005-08-24 | usos de uma enzima, de um composto antifolato e de um agente de resgate de rota de folato, sistema terapêutico, e, métodos ex vivo para clivar um grupo l-glutamato terminal de um composto, para determinar a taxa e/ou extensão de clivagem de um composto e para clivar um composto |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1917027A2 (pt) |
| AU (1) | AU2005335876A1 (pt) |
| BR (1) | BRPI0520493A2 (pt) |
| CA (1) | CA2619992A1 (pt) |
| IL (1) | IL189498A0 (pt) |
| MX (1) | MX2008002648A (pt) |
| WO (1) | WO2007023243A2 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3029483T3 (en) * | 2008-09-17 | 2025-06-24 | Endocyte Inc | Folate receptor binding conjugates of antifolates |
| TWI461410B (zh) | 2008-12-30 | 2014-11-21 | Arqule Inc | 經取代之５，６－二氫－６－苯基苯並〔f〕異喹啉－２－胺化合物類 |
| US20170239250A1 (en) * | 2016-02-19 | 2017-08-24 | Eagle Pharmaceuticals, Inc. | Pemetrexed formulations |
| WO2018031968A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| CN121177507A (zh) | 2016-08-12 | 2025-12-23 | L.E.A.F.控股集团公司 | α和γ-D聚谷氨酸化抗叶酸剂及其用途 |
| JP7491572B2 (ja) * | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化ペメトレキセドおよびその使用 |
| WO2019157121A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CN111867593A (zh) | 2018-02-07 | 2020-10-30 | L.E.A.F.控股集团公司 | α聚谷氨酸化抗叶酸剂及其用途 |
| US12310966B2 (en) | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| WO2019157145A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| EP3749318A4 (en) * | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| EP3749314A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| JP7462950B2 (ja) | 2018-02-14 | 2024-04-08 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化メトトレキセートおよびその使用 |
| CA3090753A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| WO2019160735A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| US12350271B2 (en) | 2018-02-14 | 2025-07-08 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0404487D0 (en) * | 2004-02-28 | 2004-03-31 | Protherics Molecular Design Lt | Use of enzyme |
-
2005
- 2005-08-24 AU AU2005335876A patent/AU2005335876A1/en not_active Abandoned
- 2005-08-24 EP EP05775448A patent/EP1917027A2/en not_active Withdrawn
- 2005-08-24 WO PCT/GB2005/003297 patent/WO2007023243A2/en not_active Ceased
- 2005-08-24 CA CA002619992A patent/CA2619992A1/en not_active Abandoned
- 2005-08-24 BR BRPI0520493-3A patent/BRPI0520493A2/pt not_active Application Discontinuation
- 2005-08-24 MX MX2008002648A patent/MX2008002648A/es unknown
-
2008
- 2008-02-13 IL IL189498A patent/IL189498A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007023243A3 (en) | 2007-09-07 |
| AU2005335876A1 (en) | 2007-03-01 |
| WO2007023243A2 (en) | 2007-03-01 |
| MX2008002648A (es) | 2008-03-14 |
| IL189498A0 (en) | 2008-06-05 |
| EP1917027A2 (en) | 2008-05-07 |
| CA2619992A1 (en) | 2007-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0520493A2 (pt) | usos de uma enzima, de um composto antifolato e de um agente de resgate de rota de folato, sistema terapêutico, e, métodos ex vivo para clivar um grupo l-glutamato terminal de um composto, para determinar a taxa e/ou extensão de clivagem de um composto e para clivar um composto | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| AR109170A2 (es) | Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente | |
| BRPI0706676B8 (pt) | uso de uma solução aquosa com potencial de oxirredução | |
| WO2007070052A3 (en) | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| WO2005051429A3 (en) | Targeted conjugates with a modified saccharide linker | |
| BRPI0714399B8 (pt) | composição farmacêutica líquida oral | |
| NO20083324L (no) | Multisykliske aminosyrederivater og anvendelse derav | |
| MXPA05013637A (es) | Inhibidores gsk-3 y usos de los mismos. | |
| PE20081361A1 (es) | Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas | |
| BRPI0410041A (pt) | métodos para tratamento de dor de cabeça de sinusite | |
| AR081677A1 (es) | Metodos y composiciones para la administracion intratecal de iduronato-2-sulfatasa, recipiente, sistema para administracion intratecal | |
| WO2005123116A3 (en) | Compositions and methods for treating or preventing oxalate-related disease | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| CU23367A3 (es) | Formulación de moxifloxacino con sal común | |
| PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| BRPI0416812A (pt) | métodos e reagentes para o tratamento de desordens inflamatórias | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| WO2008005560A3 (en) | Prevention of thrombotic disorders with active vitamin d compounds | |
| BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
| WO2008021048A3 (en) | Adp-ribosyltransferase based methods and compositions | |
| GT200500361A (es) | Farmaco para administracion higienica al oido | |
| CY1109541T1 (el) | Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |